CURETIS (EGFF)

signed

The project would support the company's activities in the development of molecular diagnostics tests for severe infectious diseases in hospitalised patients. The project would support the development of novel test panels, e.g. for intra-abdominal infections and sepsis host response as well as urinary tract infection, cardiology-associated infection and extended respiratory panels, as well as future panels on platforms such as the Unyvero platform. In addition, the project would support the necessary clinical trials to obtain the relevant regulatory approvals for market authorisation and reimbursement, and capital expenditure for manufacturing expansion.